Media headlines about Clearside Biomedical (NASDAQ:CLSD) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clearside Biomedical earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.6095606902289 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 15,000 Shares (americanbankingnews.com)
- Insider Selling: Clearside Biomedical, Inc. (CLSD) Director Sells 35,000 Shares of Stock (americanbankingnews.com)
- Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA… (tmcnet.com)
- Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting (finance.yahoo.com)
- Clearside Biomedical, Inc. (CLSD) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
CLSD has been the topic of several recent research reports. Cowen and Company restated a “buy” rating on shares of Clearside Biomedical in a research report on Monday, August 7th. ValuEngine downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Zacks Investment Research downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $18.33.
Shares of Clearside Biomedical (NASDAQ CLSD) traded up $0.13 during mid-day trading on Friday, hitting $7.09. The stock had a trading volume of 100,218 shares, compared to its average volume of 133,241. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.57 and a quick ratio of 4.57. Clearside Biomedical has a twelve month low of $5.44 and a twelve month high of $24.73.
Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.17). The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.01 million. Clearside Biomedical had a negative return on equity of 90.72% and a negative net margin of 17,684.07%. sell-side analysts forecast that Clearside Biomedical will post -2.33 earnings per share for the current fiscal year.
In related news, insider Daniel H. White sold 8,000 shares of the stock in a transaction on Thursday, October 19th. The stock was sold at an average price of $7.82, for a total value of $62,560.00. Following the completion of the transaction, the insider now directly owns 477,935 shares of the company’s stock, valued at approximately $3,737,451.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Clay Thorp sold 35,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $7.00, for a total value of $245,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 148,000 shares of company stock valued at $1,126,955. Corporate insiders own 20.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Clearside Biomedical (CLSD) Receives Media Sentiment Score of 0.07” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/11/19/clearside-biomedical-clsd-receives-media-sentiment-score-of-0-07.html.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.